For the year ending 2025-12-31, CRSP has $2,265,243K in assets. $343,430K in debts. $347,559K in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 347,559 | |||
| Marketable securities | 1,628,269 | |||
| Accounts receivable | 0 | |||
| Prepaid expenses and other current assets | 9,843 | |||
| Total current assets | 1,985,671 | |||
| Total property and equipment, gross | 206,903 | |||
| Accumulated depreciation | 91,052 | |||
| Property and equipment, net | 115,851 | |||
| Restricted cash | 7,629 | |||
| Operating lease assets | 131,724 | |||
| Other non-current assets | 24,368 | |||
| Total assets | 2,265,243 | |||
| Accounts payable | 11,138 | |||
| Accrued expenses | 89,407 | |||
| Deferred revenue, current | 15,771 | |||
| Accrued tax liabilities | 1,113 | |||
| Operating lease liabilities | 18,578 | |||
| Other current liabilities | 13,113 | |||
| Total current liabilities | 149,120 | |||
| Deferred revenue, non-current | 0 | |||
| Operating lease liabilities, net of current portion | 188,168 | |||
| Other non-current liabilities | 6,142 | |||
| Total liabilities | 343,430 | |||
| Common shares, chf 0.03 nominal value, 132,477,166 shares authorized at december 31, 2025 and december 31, 2024, 96,009,657 and 85,912,297 shares issued at december 31, 2025 and december 31, 2024, respectively, 95,894,341 and 85,741,981 shares outstanding at december 31, 2025 and december 31, 2024, respectively | 3,087 | |||
| Treasury shares, at cost, 115,316 and 170,316 shares at december 31, 2025 and december 31, 2024, respectively | 60 | |||
| Additional paid-in capital | 3,861,516 | |||
| Accumulated deficit | -1,947,551 | |||
| Accumulated other comprehensive income | 4,821 | |||
| Total shareholders equity | 1,921,813 | |||
| Total liabilities and shareholders equity | 2,265,243 | |||
CRISPR Therapeutics AG (CRSP)
CRISPR Therapeutics AG (CRSP)